Galapagos NV has entered into a binding framework agreement with Gilead Sciences to collaborate on developing gamgertamig, a clinical-stage BCMA×CD3 T cell engager for autoimmune diseases. Under the deal, Galapagos will receive 50% of Gilead's $1.675 billion upfront payment for acquiring Ouro Medicines plus 50% of contingent milestone payments. ...

Gilead Sciences agreed to acquire Ouro Medicines for $1.675 billion upfront plus up to $500 million in milestone payments to strengthen its inflammation and autoimmune disease pipeline. The clinical-stage drug OM336, a bispecific T cell engager, will be co-developed with Galapagos NV, which will fund 50% of upfront costs and development expenses ...

Galapagos and Gilead are in advanced discussions for a strategic partnership following Gilead's acquisition of Ouro Medicines. Under the proposed collaboration, Galapagos would co-develop OM336 (gamgertamig), a BCMA-targeted T-cell engager for autoimmune diseases, with improved financial terms including 50% cost-sharing for registration studies a...

Galapagos and Gilead are in advanced partnership discussions following Gilead's acquisition of Ouro Medicines for $1.675 billion upfront plus up to $500 million in milestone payments. Under the proposed collaboration, Galapagos would pay 50% of acquisition costs, absorb Ouro's operating assets, and lead development through registrational studies,...

U.S. stock futures were mixed on Tuesday following Monday's rally that saw the Dow Jones jump nearly 600 points to an all-time high, driven by geopolitical developments in Venezuela. Key movers include CoreWeave rising on Nvidia partnership plans, Vistra gaining on a $4.7 billion acquisition, and Microchip Technology advancing on better-than-expe...